1 |
Shin SK, Kim YS, Choi SJ, Shim YS, Jung DH, Kwon OS, Choi DJ, Kim JH. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article. Medicine (Baltimore) 2017;96:e7278. [PMID: 28723741 DOI: 10.1097/MD.0000000000007278] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
2 |
Xiong J, Luo J, Bian J, Wu J. Overall diagnostic accuracy of different MR imaging sequences for detection of dysplastic nodules: a systematic review and meta-analysis. Eur Radiol 2021. [PMID: 34357448 DOI: 10.1007/s00330-021-08022-5] [Reference Citation Analysis]
|
3 |
Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, Fusté LC, Heinz-Peer G, Judmaier W, Laniado M. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467. [PMID: 18058107 DOI: 10.1007/s00330-007-0716-9] [Cited by in Crossref: 301] [Cited by in F6Publishing: 271] [Article Influence: 20.1] [Reference Citation Analysis]
|
4 |
Yang DM, Jahng GH, Kim HC, Jin W, Ryu CW, Nam DH, Lee YK, Park SY. The detection and discrimination of malignant and benign focal hepatic lesions: T2 weighted vs diffusion-weighted MRI. Br J Radiol. 2011;84:319-326. [PMID: 20959371 DOI: 10.1259/bjr/50130643] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|